Contineum Therapeutics (CTNM) EBITDA (2023 - 2026)

Contineum Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$16.9 million for Q1 2026.

• On a quarterly basis, EBITDA rose 6.66% year-over-year to -$16.9 million in Q1 2026; TTM through Mar 2026 was -$66.9 million, a 13.17% decrease from a year earlier, with the FY2025 full-year figure at -$68.1 million, down 33.73% from the prior year.
• EBITDA rose to -$16.9 million in Q1 2026 per CTNM's latest filing, from -$17.1 million in the prior quarter.
• Across five years, EBITDA topped out at $38.9 million in Q2 2023 and bottomed at -$18.1 million in Q1 2025.
• The 4-year median for EBITDA is -$13.0 million (2024), against an average of -$9.2 million.
• Across the five-year window, EBITDA sank 128.11% in 2024 and advanced 6.66% in 2026, its largest moves.
• Year by year, EBITDA stood at -$9.7 million in 2023, then plunged by 76.18% to -$17.0 million in 2024, then declined by 0.4% to -$17.1 million in 2025, then increased by 1.23% to -$16.9 million in 2026.
• Per Business Quant, the three latest CTNM EBITDA figures stand at -$16.9 million (Q1 2026), -$17.1 million (Q4 2025), and -$14.9 million (Q3 2025).